FDA cosmetic product listing requirements: what to file, and what keeps it true

The listing duty sits with the Responsible Person, defined as the manufacturer, packer or distributor whose name appears on the product label under the Fair Packaging and Labeling Act. That is a label question, not a contractual one. If your brand name is on the front of the pack, you are the Responsible Person, whether or not the contract manufacturer offers to file for you.

The Responsible Person also holds the safety substantiation for the product, receives adverse event reports and is the FDA's named contact. A distributor putting its own name on an imported product becomes the Responsible Person for that product, which frequently surprises private label buyers.

A single listing may cover multiple cosmetic products with identical formulations, or formulations that differ only with respect to colours, fragrances, flavours or quantity of contents. That is how a 24-shade foundation range becomes one listing rather than 24, provided the base formulation is the same.

Listings must be updated annually. Where nothing has changed, an abbreviated renewal confirming no change is acceptable, but silence is not. Beyond the annual cycle, the listing has to reflect reality, and reality changes for reasons that never start in the regulatory team.

• Formulation change. A preservative swap, a supplier substitution with a different INCI, a fragrance reformulation to meet an allergen limit. Each one changes the ingredient list on the listing.
• Manufacturing change. Moving a SKU from one filling site to another changes the facility registration numbers the listing quotes.
• Label change. A renamed product or a rebranded range changes the product name of record.
• Discontinuation. A product no longer marketed should be reflected, not left listed indefinitely.
• Responsible Person change. A distributor change or a brand acquisition moves the duty to a different legal entity.

None of these are hard to file. The difficulty is knowing they happened. In most brands, the ingredient change lives in R&D, the site transfer lives in supply chain, and the rename lives in marketing. The listing is downstream of all three.

• Listings. 40 SKUs collapse to 26 listings once shade variants of three colour cosmetic ranges are grouped under shared base formulations.
• Facilities. Each listing quotes one or two facility registration numbers. Two SKUs are dual-sourced, so both numbers appear.
• Annual cycle. 26 abbreviated renewals, of which nine are genuine updates because of reformulation or a site move during the year.
• The failure point. A supplier discontinued a botanical extract in March. Procurement approved an equivalent from a second supplier with a different INCI name. The batch record changed, the label was reprinted at the next run, and the listing was not touched until the following February. For eleven months the FDA held an ingredient list that did not match the pack.
• What fixes it. Not more diligence. A formula record where an approved substitution automatically raises the label, the listing and the safety substantiation review as linked tasks.

A brand selling in the US, EU and UK files three different things from broadly the same data: a MoCRA product listing, an EU CPNP notification and a UK SCPN notification. The formats differ, the thresholds differ, and the responsible party differs, but the underlying ingredient, concentration and label data is the same dataset.

Running them as three parallel processes is what makes multi-market compliance expensive. Holding the formula, the label and the facility once, then generating each market's filing from it, is what makes it routine.